| # | Title | Journal | Year | Citations |
|---|
| 1 | Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 | Molecular Therapy | 2010 | 2,079 |
| 2 | Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells | Molecular Therapy | 2013 | 1,314 |
| 3 | A Novel Nanoparticle Drug Delivery System: The Anti-inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes | Molecular Therapy | 2010 | 1,267 |
| 4 | Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection | Molecular Therapy | 2008 | 1,143 |
| 5 | Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability | Molecular Therapy | 2008 | 1,106 |
| 6 | Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-inflammatory Drugs From the Nasal Region to the Brain | Molecular Therapy | 2011 | 1,070 |
| 7 | Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo | Molecular Therapy | 2009 | 988 |
| 8 | A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy | Molecular Therapy | 2005 | 967 |
| 9 | Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications | Molecular Therapy | 2015 | 877 |
| 10 | T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis | Molecular Therapy | 2011 | 857 |
| 11 | Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms | Molecular Therapy | 2010 | 831 |
| 12 | Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes | Molecular Therapy | 2005 | 773 |
| 13 | Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy | Molecular Therapy | 2006 | 744 |
| 14 | Effect of Genome Size on AAV Vector Packaging | Molecular Therapy | 2010 | 713 |
| 15 | Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation | Molecular Therapy | 2012 | 702 |
| 16 | Cellular Uptake of Arginine-Rich Peptides: Roles for Macropinocytosis and Actin Rearrangement | Molecular Therapy | 2004 | 688 |
| 17 | Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery | Molecular Therapy | 2019 | 685 |
| 18 | Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous System | Molecular Therapy | 2004 | 669 |
| 19 | Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer | Molecular Therapy | 2008 | 651 |
| 20 | Codon-Optimized Gaussia Luciferase cDNA for Mammalian Gene Expression in Culture and in Vivo | Molecular Therapy | 2005 | 635 |
| 21 | Lipid Nanoparticle Systems for Enabling Gene Therapies | Molecular Therapy | 2017 | 632 |
| 22 | Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice | Molecular Therapy | 2011 | 610 |
| 23 | The Possible “Proton Sponge ” Effect of Polyethylenimine (PEI) Does Not Include Change in Lysosomal pH | Molecular Therapy | 2013 | 593 |
| 24 | Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3-Dioxygenase and Bystander M2 Macrophage Differentiation | Molecular Therapy | 2012 | 582 |
| 25 | The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls | Molecular Therapy | 2010 | 578 |
| 26 | Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity | Molecular Therapy | 2013 | 578 |
| 27 | Progress towards in Vivo Use of siRNAs | Molecular Therapy | 2006 | 567 |
| 28 | History of Oncolytic Viruses: Genesis to Genetic Engineering | Molecular Therapy | 2007 | 567 |
| 29 | Adenoviruses as vaccine vectors | Molecular Therapy | 2004 | 564 |
| 30 | RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System | Molecular Therapy | 2006 | 549 |
| 31 | Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma | Molecular Therapy | 2007 | 531 |
| 32 | Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8 | Molecular Therapy | 2006 | 527 |
| 33 | Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo | Molecular Therapy | 2006 | 524 |
| 34 | Repair of Tissues by Adult Stem/Progenitor Cells (MSCs): Controversies, Myths, and Changing Paradigms | Molecular Therapy | 2009 | 524 |
| 35 | FDA-Approved Oligonucleotide Therapies in 2017 | Molecular Therapy | 2017 | 524 |
| 36 | Genome-editing Technologies for Gene and Cell Therapy | Molecular Therapy | 2016 | 523 |
| 37 | Stem and Progenitor Cells in Skeletal Muscle Development, Maintenance, and Therapy | Molecular Therapy | 2007 | 522 |
| 38 | Control of Endothelial Targeting and Intracellular Delivery of Therapeutic Enzymes by Modulating the Size and Shape of ICAM-1-targeted Carriers | Molecular Therapy | 2008 | 506 |
| 39 | Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration | Molecular Therapy | 2010 | 503 |
| 40 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma | Molecular Therapy | 2017 | 498 |
| 41 | Grape Exosome-like Nanoparticles Induce Intestinal Stem Cells and Protect Mice From DSS-Induced Colitis | Molecular Therapy | 2013 | 495 |
| 42 | Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses | Molecular Therapy | 2017 | 489 |
| 43 | Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy | Molecular Therapy | 2010 | 488 |
| 44 | IRES-Dependent Second Gene Expression Is Significantly Lower Than Cap-Dependent First Gene Expression in a Bicistronic Vector | Molecular Therapy | 2000 | 481 |
| 45 | Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation | Molecular Therapy | 2006 | 454 |
| 46 | A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates | Molecular Therapy | 2018 | 452 |
| 47 | Internalized Antigens Must Be Removed to Prepare Hypoimmunogenic Mesenchymal Stem Cells for Cell and Gene Therapy | Molecular Therapy | 2004 | 448 |
| 48 | Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons | Molecular Therapy | 2009 | 444 |
| 49 | Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication | Molecular Therapy | 2010 | 442 |
| 50 | Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo | Molecular Therapy | 2003 | 435 |
